Subscribe to:
POZ magazine E-newsletters
POZ Personals Sign In / Join
Username:
Password:

Back to home » Treatment News » Top Stories

Most Popular Stories
H1N1 (Swine Flu) and You
Life Expectancy With HIV Increases Dramatically
HIV Associated With Marked Declines in Lung Function
Is Marijuana as Effective as OTC and Prescription Drugs?
HPV Vaccine Is Active in MSM
MACS Turns 25: The Influential HIV Study Continues
What's That Mean?
(just double-click it!)

If you don't understand one of the words in this article, just double-click it. A window will open with a definition from CancerWEB's On-line Medical Dictionary. If the double-click feature doesn't work in your browser, you can enter the word below:

Most Popular Lessons
The HIV Life Cycle
Shingles
Herpes Simplex Virus
Syphilis & Neurosyphilis
Treatments for Opportunistic Infections (OIs)
What is AIDS & HIV?
More News

Have medical or treatment news about HIV? Send press releases, news tips and other announcements to editors@aidsmeds.com.

Click here for more news


emailrssprint

April 25, 2008

Treatment Failure: Symptoms Matter Too

Symptoms of failing health are nearly as effective as viral loads or CD4 counts in determining if an antiretroviral (ARV) treatment regimen has stopped working and needs to be switched, according to new research published in The Lancet and reported by AIDSmap. These findings have important implications in developing countries, where shortages of viral load and CD4 tests are delaying the rollout of much needed ARV therapy. 

Using data from a number of cohort studies, Andrew Phillips, MD, of the Royal Free and University College Medical School in London, and his colleagues designed a computerized system to predict short- and long-term survival in people switching from a first to a second ARV regimen. They asked the system to predict survival if people switched following a viral load result above 500 copies, a CD4 drop of at least 50 percent from the highest measure after starting treatment, or based on a set of HIV-related symptoms maintained by the World Health Organization (WHO). Survival five years after a switch was 82 to 83 percent for each of the three models. It was only after 20 years where switching due to symptoms performed significantly less well than CD4 count or viral load.

The authors concede that computer simulations are not equal to clinical studies, and that their results stand in contrast to a clinical study conducted in Uganda in 2003 and 2004. However, they still conclude that these data support arguments favoring the distribution of ARV therapy in countries that do not have access to the viral load or CD4 tests that are typically used as a component of follow-up care in industrialized nations.

Search: CD4, viral load, Royal Free, Andrew, Phillips, Uganda, WHO


Scroll down to comment on this story.

emailrssprint

Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The AIDSmeds team review all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

| Posting Rules

Previous Comments:

       


[Go to top]

Get Started
Get Answers
I'm HIV positive. What's next?
How to find a support system
Things you should know before starting treatment
How to handle side effects and other concerns
How to tell someone you have HIV/AIDS
Conference Coverage

CROI 2009
Montréal, Canada
February 8-11, 2009


48th Annual ICAAC/IDSA 46th Annual Meeting
Washington, DC
October 25-28, 2008


XVII International AIDS Conference
Mexico City, Mexico
August 3-8, 2008


more conference coverage


[ about AIDSmeds | AIDSmeds advisory board | our staff | advertising policy | advertise/contact us]